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Placental  malaria  (PM)  due  to Plasmodium  falciparum  is  a major  cause  of  maternal,  fetal  and  infant  mortal-
ity, but  the mechanisms  of  pathogenesis  and  protective  immunity  are  relatively  well-understood  for  this
condition,  providing  a path  for vaccine  development.  P. falciparum  parasites  bind  to  chondroitin  sulfate
A  (CSA)  to sequester  in  the  placenta,  and  women  become  resistant  over  1–2 pregnancies  as  they  acquire
antibodies  that block  adhesion  to CSA.  The  protein  VAR2CSA,  a member  of  the  PfEMP1  variant  surface
antigen  family,  mediates  parasite  adhesion  to  CSA,  and  is  the  leading  target  for  a vaccine  to  prevent
PM.  Obstacles  to  PM  vaccine  development  include  the  large  size  (∼350 kD),  high  cysteine  content,  and
sequence  variation  of  VAR2CSA.  A  number  of  approaches  have  been  taken  to  identify  the  combination  of
VAR2CSA  domains  and  alleles  that  can  induce  broadly  active  antibodies  that block  adhesion  of  heterolo-
gous  parasite  isolates  to CSA.  This review  summarizes  these  approaches,  which  have examined  VAR2CSA
fragments  for binding  activity,  antigenicity  with  naturally  acquired  antibodies,  and  immunogenicity  in
animals  for  inducing  anti-adhesion  or surface-reactive  antibodies.  Two  products  are  expected  to  enter
human  clinical  studies  in the  near future  based  on  N-terminal  VAR2CSA  fragments  that  have high  bind-
ing  afﬁnity  for CSA,  and  additional  proteins  preferentially  expressed  by  placental  parasites  are  also  being
examined  for  their  potential  contribution  to a PM  vaccine.
d  by ©  2015  Publishe
. Introduction
Placental malaria (PM) leads to poor outcomes for pregnant
omen and their babies, and is caused by Plasmodium falciparum
equestration in the intervillous spaces of placenta and the ensuing
nﬂammation. Severe maternal anemia, low birth weight delivery
nd fetal loss are common sequelae, resulting in 10,000 maternal
eaths and 200,000 infant deaths annually in Africa by some esti-
ates, and causing a third of perinatal mortality in the absence of
reventive measures [1]. The poor outcomes of PM have been asso-
iated with the inﬂammatory inﬁltrates and levels of inﬂammatory
ytokines observed in the placenta [2–6]. Adult residents of malaria
ndemic areas enjoy immunity that protects them from severe dis-
ase; women become susceptible to infection and disease again
uring ﬁrst gestation, then regain immunity over successive preg-
ancies. P. falciparum infected erythrocytes (IE) bind chondroitin
ulfate A (CSA) on the syncytiotrophoblast surface and in intervil-
ous spaces; unlike placental IE, IE in non-pregnant individuals bind
 Open Access provided for this article by the PATH Malaria Vaccine Initiative and
xxonMobil Foundation.
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receptors like CD36 and ICAM-1 but not CSA to sequester in other
vascular beds [7].
With increasing parity, women acquire speciﬁc antibody against
CSA-binding parasites, including that which inhibits IE adhesion,
and this antibody is associated with heavier babies and higher
maternal hemoglobin levels [8–10]. These naturally acquired anti-
bodies are broadly active to placental IE collected around the world,
indicating that the target epitopes are conserved [11]. This model
of pathogenesis and immunity provides a framework to develop
PM vaccines, and also predicts that vaccine-induced immunity
should be naturally boosted when pregnant women are exposed to
malaria. Other malaria parasite species such as Plasmodium vivax
infect pregnant women, but disease sequelae are less severe [12],
and these species do not sequester in placenta [13] hence the
path to a vaccine against these forms of pregnancy malaria is not
clear.
P. falciparum IE adhesion to CSA is mediated by the large
(∼350 kD) protein called VAR2CSA (Fig. 1), a member of the
PfEMP1 variant surface antigen family. PfEMP1 proteins includ-
ing VAR2CSA are encoded in the genome of P. falciparum but
not that of other human malaria parasites. VAR2CSA has extra-
cellular, transmembrane, and intracytoplasmic regions, and its
extracellular region is uniquely structured among PfEMP1 fam-
ily members. The extracellular region of VAR2CSA includes an
N-terminal sequence, 6 cysteine-rich Duffy binding like (DBL)
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Domain architecture of VAR2CSA. Schematic organization of VAR2CSA protein, showing its N-terminal sequence, 6 cysteine-rich Duffy binding like (DBL) domains,
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Anter-domain (ID) regions, and intracytoplasmic tail (acidic terminal sequence, ATS).
s  the number of single nucleotide polymorphisms (SNPs) per 100 nucleotides, meas
ifferences. SNP data obtained from PlasmoDB. Figure and sequence analysis prepa
omains, and inter-domain (ID) regions that increasingly appear
o play a key role in adhesion and immunogenicity of recombinant
AR2CSA protein fragments. VAR2CSA is preferentially expressed
y placental parasites and isolates selected to bind CSA [14,15], and
s currently the leading candidate for a vaccine to prevent malaria
uring pregnancy. The high molecular weight, multiple extra-
ellular domains, and extensive sequence variation of VAR2CSA
ose unique challenges in designing a vaccine that will mimic  the
roadly neutralizing activity of naturally acquired immunity. The
ost challenging step is to deﬁne the domain or domain combina-
ion and boundaries that can elicit potent pan-reactive antibody.
urrently, the ﬁrst 2 candidate VAR2CSA-based products derived
rom the protein N-terminus region are entering clinical trials
valuation.
We review here the approaches to design VAR2CSA immuno-
ens that can be used in a vaccine to prevent PM,  either by deﬁning
SA-binding fragments of VAR2CSA, or by deﬁning the domains and
pitopes that induce broadly active antibodies in animals or that
eact to such antibodies from immune women. We  conclude with
 discussion of the antigens other than VAR2CSA that are preferen-
ially expressed by placental parasites, as these may  also contribute
o a protective vaccine.
. CSA-binding domains of VAR2CSA
PM vaccine development is currently based on mimicking natu-
ally acquired functional antibodies that block parasite adhesion to
SA. Because these antibodies are likely to target epitopes within
he binding domains of VAR2CSA, several approaches have been
pplied to identify CSA binding regions of the protein. Initial in vitro
tudies examined binding to CSA of 6 VAR2CSA recombinant DBL
omains of 3D7 allele and the DBL1, DBL2 and DBL3 of the A4 allele:
BL2 and DBL6 domains of 3D7 and DBL2 and DBL3 of A4 bound
mmobilized CSA [16,17]. In another study, DBL3 of both 3D7 and A4
lleles bound CSA, but the 3D7 form demonstrated stronger binding
han the A4 form [18]. Following these observations, two crystal-
ography studies using recombinant DBL3 protein of the A4 allele
onﬁrmed binding to CSA [19,20].
In another approach to identify CSA binding motifs, a phage
ibrary of var2csa gene fragments was panned on CSA-expressing
ells or soluble CSA, and identiﬁed CSA-binding peptides derived
rom the ﬁrst ﬁve domains (DBL1 through DBL5) and not DBL6
21]. Based on these results, peptides representing the sequences
f the phage clones were synthesized. One of the peptides from
BL2 domain bound to CSA and anti-peptide antibodies recognized
ative VAR2CSA [21].
In vitro binding studies have shown that DBL domains bind
peciﬁcally to CSA but not to the closely related glycosaminoglycan
hondroitin sulfate C. However, similar results have been obtained
ith DBL from other PfEMP1s expressed by IE that do not bind CSA
22]. This raises questions about data interpretation and compli-
ates identiﬁcation of speciﬁc binding domains and vaccine targets.
fter the full-length extracellular region of VAR2CSA was expressedlence of sequence variability along the extent of the protein is graphically displayed
s a moving average along the sequence. Analysis does not include insertion/deletion
 Robert Morrison.
as recombinant protein, individual DBL domains or domain combi-
nations were re-evaluated using the full-length protein as a bench
mark for strength of binding. Full length VAR2CSA binds CSA at
a nanomolar afﬁnity [23,24]. Kinetic analysis showed that single
domains DBL2, DBL3 and DBL6 bind CSA with afﬁnity in the micro-
molar range [24,25]. In comparison, recombinant multi-domain
DBL1–ID1–DBL2 fragment bound CSA with similar kinetics as the
full length protein in one study [25], but did not bind CSA in another
study [26]. Instead, the latter study found high afﬁnity binding
with DBL1–ID1–DBL2–ID2a domain combination. ID2a and ID2b
comprise the so-called cysteine-rich inter-domain region (CIDR) of
VAR2CSA, and the evidence suggested that ID2a or a portion of it
is required for speciﬁc binding to CSA and not to other sulfated
glycans [26]. For example, recombinant DBL1–ID1–DBL2–CIDR
(ID2a–ID2b) binds to CSA and to heparan sulfate equally, while
a recombinant protein truncated after the ﬁrst 90–100 amino
acids of ID2a regained speciﬁcity [26]. Interestingly, the binding
of DBL1–ID1–DBL2 to decorin was  stronger than to CSA [25], a dif-
ference that was not seen in binding of intact IE (unpublished data)
and that may  reﬂect differences between the native epitopes and
the binding epitopes of the recombinant protein. In summary, it
appears that the highest binding afﬁnity to CSA was  obtained with
domain combinations from the N-terminal portion of VAR2CSA, but
the speciﬁcity of binding is inﬂuenced by inclusion or exclusion of
different CIDR (ID2a–ID2b) fragments.
3. Naturally acquired antibodies to VAR2CSA domains
Over successive pregnancies women  develop speciﬁc immu-
nity to the parasites that sequester in the placenta. Antibodies that
block parasite adhesion to CSA have been associated with a reduced
infection risk and increased newborn birthweight [8,10,11]. Low
antibody reactivity with the IE surface was  associated with lower
hemoglobin level and reduced birthweight [9]. Antibodies that
react to the IE surface by ﬂow, or that opsonize or agglutinate CSA-
binding IE, also develop in naturally exposed women  [9,27–38],
although the evidence base is smaller that these antibodies might
be associated with clinical outcomes.
Because VAR2CSA is the leading vaccine target, several stud-
ies have compared VAR2CSA domains for reactivity to sera of
primigravid and multigravid women  in order to support vaccine
design (Table 1). Tuikue Ndam et al. [39] reported that antibod-
ies to domains DBL5 and DBL6 but not DBL1 measured during
the 2nd trimester or at delivery correlated with parity in an area
of Senegal with seasonal malaria transmission. In a recent study
from Benin, Tuikue Ndam et al. [10] reported that antibody levels
to DBL1–ID1–DBL2 and to DBL3 were higher among multigravid
than primigravid women  both during pregnancy and at the time
of delivery, while antibody levels to DBL4 or DBL5 were only
higher in multigravid women  at delivery or during pregnancy,
respectively. Babakhanyan et al. [40] reported that antibody levels
to ID1–DBL2–ID2a did not differ between Cameroonian pregnant
women and men. Similarly, Gnidehou et al. [41] reported that in
M. Fried, P.E. Duffy / Vaccine 
Table  1
Studies of acquired antibody to VAR2CSA DBL domains in African women, indicating
the relationship between antibody levels and maternal parity. Timing of sample
collection during pregnancy or delivery is indicated.
DBL
domain
Signiﬁcant increase with
parity
No difference with parity
DBL1 Oleinikov [42] (Delivery) Tuikue Ndam [39]
(Enrollmenta & Delivery)
DBL1–DBL2 Tuikue Ndam [10]
(Enrollmenta & Delivery)
ID1–ID2a Babakhanyanb [40]
DBL3 Oleinikov [42] (Delivery)
Tuikue Ndam [10]
(Enrollmenta & Delivery)
Brolin [33] (3rd trimester)
DBL4 Tuikue Ndam [10] (Delivery) Oleinikov [42] (Delivery)
Tuikue Ndam [10]
(Enrollmenta)
DBL5 Brolin [33] (3rd trimester)
Gangnard [44] (During
pregnancy)c
Gnidehou [43] (2nd and 3rd
trimester)
Salanti [14] (Delivery)
Tuikue Ndam [39]
(Enrollmenta & Delivery)
Tuikue Ndam [10]
(Enrollmenta)
Oleinikov [42] (Delivery)
Tuikue Ndam [10] (Delivery)
DBL6 Oleinikov [42] (Delivery)
Tuikue Ndam [39]
(Enrollmenta & Delivery)
Brolin [33] (3rd trimester)
Tuikue Ndam [10]
(Enrollmenta & Delivery)
a Samples collected at enrollment at any time during the ﬁrst 6 months of gesta-
tion.
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c Samples collected during pregnancy, but timing is not speciﬁed.
olombia, children, men  and pregnant women exposed to malaria
ave similar antibody levels to ID1–DBL2–ID2a, DBL3 and DBL5
omains. Oleinikov et al. [42] reported signiﬁcantly higher levels
f antibodies to DBL1, DBL3 and DBL6 (but not DBL4 or DBL5)
n multigravidae compared to primigravidae living in a malaria
oloendemic area of Tanzania. Brolin et al. [33] found that anti-
odies to DBL5 were higher among multigravid compared to prim-
gravid women, while antibody levels to DBL3 and DBL6 did not
iffer by gravidity. Several other studies reported parity-dependent
erum reactivity to DBL5 domain [14,43,44]. In summary, parity-
ependent acquisition of VAR2CSA-speciﬁc antibody appears to be
 robust correlate of protective immunity, but in general it does not
ppear to discriminate well between different candidate VAR2CSA
mmunogens. Further, studies differ as to whether a particular
omain speciﬁcity is elevated in multigravid women, possibly due
o differences in recombinant antigens, in assay format such as
LISA versus Luminex platform, or in study populations.
More data are emerging on the relationships between antibod-
es to DBL domains and birthweight or maternal anemia. Tutterrow
t al. [45] examined antibody levels to DBL1, DBL1–ID1–DBL2,
BL3, DBL4, DBL5, and DBL6 of 3 alleles over the course of preg-
ancy in Cameroon, and concluded that the number of domains
nd allelic types recognized by naturally acquired antibodies during
econd trimester predicted a reduction in placental infection status
t delivery. Among Kenyan women with acute or chronic malaria
nfection, higher antibody levels to DBL5 were associated with
educed risk of low birthweight delivery and with increased birth-
eight [14]. In Mozambique, antibody levels to VAR2CSA domains,
o merozoite antigens (EBA-175 and MSP1), and to IE surface were
ower among uninfected pregnant women compared to pregnant
omen with acute, chronic or past infection. Among women  with
t least one malaria infection during their pregnancy, high anti-
ody levels to VAR2CSA domains and other proteins not unique
o placental parasites like AMA-1, positively correlated with birth-
eight and gestational age [46]. In a recent study in Benin, high33 (2015) 7483–7488 7485
antibody levels to the full recombinant VAR2CSA and DBL3 domain
at enrollment (before gestational week 24) were associated with
a reduction in the risk of infection in the period between enroll-
ment and delivery; reduced placental malaria risk was  associated
with higher antibody levels to DBL3, although a similar trend was
also observed with an unrelated VSA [10], and high antibody lev-
els to DBL1–ID1–DBL2 were associated with a reduction in low
birthweight deliveries [10].
4. VAR2CSA immunization of animals to elicit
anti-adhesion antibodies
VAR2CSA is a large molecular weight protein that cannot be
commercially manufactured as a full-length recombinant molecule
with existing technologies. Identifying smaller fragments that elicit
functional antibodies similar to those induced by natural infec-
tion has probably been the greatest challenge for VAR2CSA vaccine
development. Multiple studies have examined functional activ-
ity of antibodies raised in animals to DBL domains of VAR2CSA,
as an approach to identify the optimal VAR2CSA-based immuno-
gen(s) for inducing cross-reactive and/or functional antibodies. An
important caveat for these studies is that different groups use dif-
ferent assay formats to measure anti-adhesion activity of antibody,
and therefore it is not possible to compare activity measurements
between studies.
Multi-domain fragments NTS–DBL1–ID1–DBL2, DBL3–DBL4
and DBL5–DBL6 of FCR3 allele induced antibodies that reacted
with the surface of homologous parasites at higher levels than did
antibodies induced by the six single DBL domains of FCR3 allele
[47]. However, antibodies to the single DBL4 domain almost com-
pletely inhibited the binding of homologous and 2 heterologous IE
to CSA [47,48] while antibodies to other single or multi-domain
immunogens only reduced homologous parasite binding to CSA
by 50–60% [47]. Anti-adhesion antibodies induced by immuniza-
tion with DBL4 domain of FCR3 allele were species-dependent:
anti-adhesion activity was observed in samples collected from
immunized rats but not from rabbits [48]. Antibodies raised to all
DBL domains of 3D7 allele type reduced the adhesion of heterolo-
gous FCR3 IE by 50–65% compared to control, with the exception
of antibodies to DBL1 that almost completely inhibited FCR3 bind-
ing to CSA [49]. Antibodies to DBL4 of 3D7 allele as well as that of
a placental parasite sample reduced the binding of heterologous
maternal parasites by more than 50% [50]. Of the DBL domains of
HB3 allele, only DBL3 induced anti-adhesion antibodies that almost
completely inhibited the binding of FCR3 IE to CSA [49]. Other
studies reported that recombinant DBL5 domain and the multi-
domain DBL5–DBL6 of several allelic forms inhibited the binding
of FCR3 IE by more than 60% [51] and the binding of culture-
adapted isolates from pregnant women [50]. The N-terminal region
of VAR2CSA, NTS–DBL1–ID1–DBL2, elicited antibodies that almost
completely inhibited the binding of homologous FCR3 and het-
erologous HB3 IE [52], consistent with an earlier study reporting
anti-adhesion activity by antibodies raised against multidomain
immunogens including NTS–DBL1–ID1–DBL2 [47]. Smaller frag-
ments of the N-terminal region of VAR2CSA like ID1–DBL1–ID2a
and ID1–DBL2–ID2a–ID2b also elicited strong homologous anti-
adhesion antibodies [26].
Antibody anti-adhesion activity against IE collected from
pregnant women  has also been induced by the FCR3 allelic forms
of DBL4 and of N-terminal multi-domain fragments of VAR2CSA.
DBL4 domain of FCR3 inhibited 5/13 isolates from binding to
CSA by >50% [53]. An extended form of DBL4 with an additional
C-terminal 40 amino acids had broader anti-adhesion activity,
inhibiting 10/13 maternal isolates by >50% [53]. In separate stud-
ies, antibodies raised in mice and rats to DBL4 failed to inhibit the
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inding of maternal isolates [52,54]. A recent analysis of the cross
eactivity of this form showed minimal activity against heterolo-
ous isolates selected for CSA binding [55]. DNA vaccination with
TS–DBL1–ID1–DBL2 elicited antibodies that blocked the binding
f the majority of the isolates to CSA by >50% (FCR3 allele: 12/15;
D7 allele: 13/18; FCR3 allele: 11/18) [52,56]. The smaller fragment
D1–DBL2 reduced the binding to CSA of 6/8 maternal isolates, of
hich the reduction was signiﬁcant for 2 isolates [57].
Notably antibodies to the full length VAR2CSA inhibited the
inding of homologous parasite isolate [23,58] but not heterolo-
ous parasites [56,58]. Previously we showed that plasma from
ultigravid women inhibited the binding of maternal isolates in
 strain independent manner [11]. Thus, it is not clear whether
mmunization with multiple allelic types is required to induce
roadly reactive antibodies, or whether animal immunization with
ecombinant protein induces a response to different and possibly
ore variant epitopes than does natural infection, resulting in a
train-dependent response.
. Epitope mapping
Immune multigravid women develop strain-independent func-
ional antibodies against placental parasites, and these antibodies
re associated with clinical protection. Identifying epitopes tar-
eted by protective antibodies can facilitate development of a
roadly reactive vaccine to prevent pregnancy malaria. Several
pproaches have been applied to identify protective epitopes,
ncluding screening of peptide libraries, producing nanobody,
nd developing monoclonal antibodies from B cells of immune
omen.
For screening peptide libraries, Pepscan analysis was performed
n a peptide array corresponding to the extracellular portion
f VAR2CSA [59]. Pooled plasma from immune women recog-
ized multiple peptides across all VAR2CSA domains, except for a
mall reduction in reactivity with peptides corresponding to DBL2
omain; most reactivity was not reduced after depleting the plasma
n native VAR2CSA protein [59].
Antibodies to the DBL4 domain raised in rats had adhesion
locking activity against homologous and heterologous parasites
47,53]. Using a DBL4 peptide array, the reactivity of anti-DBL4
ntisera to 3 regions within DBL4 was associated with adhesion
locking activity [60]. This region was also recognized by sera
rom 4/6 immune women, with reactivity directed to a conserved
equence in DBL4 [60]. However, antibodies raised to these pep-
ides neither reacted with VAR2CSA expressed on the IE surface
or inhibited parasite adhesion to CSA. One possible explanation is
hat the linear epitopes did not mimic  the conformational epitopes
equired to induce functional antibodies [60]. Recombinant DBL4
utated in the region corresponding to the peptides recognized by
ative sera induced antibodies with lower adhesion blocking activ-
ty than the wild type form. The loss of potency may  have resulted
rom a change in a speciﬁc B-cell epitope, or alternatively from a
hange in the overall protein folding resulting in a less immuno-
enic protein [60].
Nanobody technology has been used as another approach to
dentify vaccine targets in VAR2CSA. This technology is based on
amelid heavy-chain only antibody in which the variable heavy
hain (VHH) alone comprises the antigen binding site. Recombi-
ant forms of the VHH are called nanobodies. Using this approach,
anobodies that reacted with the recombinant DBL domains
D1–DBL1–ID2a, DBL4, DBL5, and DBL6 [61] and DBL1, DBL4, DBL5,
nd DBL6 [62] were produced. Several nanobodies to DBL1 and
D1–ID2a reduced parasite adhesion to CSA while nanobodies to
BL4, DBL5 and DBL6 had no inhibitory activity [61,62]. In one
tudy, the majority of nanobodies reacted to DBL1 domain [62],
hile the other study did not identify any nanobodies to this33 (2015) 7483–7488
domain [61], making it difﬁcult to determine the utility of this
information for designing a vaccine.
Finally, B cells from immune African women  were immortalized
as a source of speciﬁc reagents, and using this approach 8 mono-
clonal antibodies that reacted with the surface of CSA-selected
isolates were identiﬁed [63]. Of those, 3 monoclonal antibodies
reacted with recombinant DBL3 domain and 4 with DBL5 domain
of VAR2CSA; the 8th monoclonal antibody named PAM1.4 did not
react with recombinant DBL domains and reacted poorly with full
length VAR2CSA [63,64]. Monoclonal antibody PAM1.4 recognized
the surface of placental parasites and inhibited their adhesion to
CSA, while it only moderately inhibited the adhesion to CSA of the
laboratory isolate FCR3-CSA [64]. These results raised an impor-
tant issue that maternal parasites may  express additional proteins
mediating adhesion to CSA that are targeted by natural immunity
and are not expressed in model laboratory isolates selected for CSA
binding phenotype.
Taken together, these different approaches to epitope map-
ping have provided insights into domains or epitopes that react to
functional antibody. However, these studies have not deﬁnitively
identiﬁed a single VAR2CSA fragment that is the ideal target for a
vaccine.
6. Invariant proteins expressed by placental parasites
In addition to VAR2CSA, several conserved proteins expressed
by placental parasites have been identiﬁed in transcriptomic and
proteomics analysis of placental parasites. While gene knockout
studies have demonstrated that VAR2CSA is required to main-
tain the CSA-binding phenotype [65], other genes and proteins are
upregulated in placental parasites and therefore might contribute
to the binding phenotype or to placental malaria pathogenesis as
well. Comparative transcriptome analyses identiﬁed 11 genes that
were upregulated in placental parasites compared to children’s
parasites [66] and 38 genes in placental parasites compared to the
reference parasite line 3D7 [67]. Two  comparative proteomics anal-
yses of placental parasites identiﬁed 17 and 53 conserved proteins
respectively that were expressed exclusively or at higher levels
in placental parasites than in parasites collected from children
[68,69]. Because these novel genes and proteins are upregulated
in VAR2CSA-expressing parasites, studies should be undertake
to determine whether deletion of VAR2CSA may  inﬂuence their
expression or localization.
Two conserved proteins PFB0115w and PFI1785w were com-
mon  between three (PFB0115w) or four (PFI1785w) comparative
studies. PFB0115w is expressed at higher levels in placental para-
sites compared to children’s isolates, while PFI1785w is exclusively
expressed by placental parasite. PFI1785w is a member of the Plas-
modium helical interspersed subtelomeric family, and is annotated
as an exported protein. Antibodies to a recombinant form of
PFI1785w reacted with membrane protein extracted from pla-
cental parasites but not with membrane proteins extracted from
children’s isolates or FCR3 parasites selected to bind CSA [68]. Anti-
body levels to recombinant PFI1785w are signiﬁcantly higher in
plasma from pregnant women than men [67]. Antibody to recom-
binant PFI1785w expressed in Escherichia coli failed to react with
the surface of live IE, suggesting that the antibody recognizes
non-conformational epitopes [68]. Further studies with protein
expressed in a eukaryotic system that better reﬂects native struc-
ture could be valuable for studies of localization and adhesion to
CSA.Of 5 conserved genes that were upregulated in transcriptomic
studies of placental parasites [66], one of the proteins named
PfCSAL binds to CSA and co-localizes with VAR2CSA on the sur-
face of maternal IE (Keitany, Duffy, et al., unpublished data). This
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rotein is currently being evaluated as an additional placental
alaria vaccine candidate.
. Summary
The rational design of a vaccine to prevent malaria during preg-
ancy is based on the observations that a distinct form of the
arasite that infects the placenta is associated with disease and
eath in mothers and newborns, and that women become resistant
o pregnancy malaria as they develop antibodies against proteins
xpressed on the surface of this parasite form. The identiﬁcation of a
ingle human monoclonal antibody (PAM1.4) from immune multi-
ravid women that recapitulates anti-adhesion activity in plasma
rom multigravidae [64], together with the observation that plasma
rom multigravidae have strain-transcending functional activity
11], strongly suggest that a limited number of epitopes can be
argeted by an effective PM vaccine.
Currently, VAR2CSA is the leading pregnancy malaria vaccine
andidate. Different research approaches have been taken to iden-
ify the targets that should be included in a VAR2CSA-based
accine, including mapping the CSA-binding sites, mapping anti-
ody epitopes, deﬁning DBL domains preferentially recognized
y immune sera, and assessing functional activity by antibodies
aised against recombinant DBL domains. While multiple VAR2CSA
omains bind CSA in in vitro assays, an N-terminal fragment
ID1–DBL2–ID2a–ID2b) binds CSA with similar kinetics as the full
ength protein [26]. Antibody levels to N-terminal fragments of
AR2CSA are similar between men, primigravid and multigravid
omen in Africa [40]. However, antibodies induced in animals to
he NTS–DBL1–ID1–DBL2–ID2a multi-domain have heterologous
unctional activity, and the serum activity induced by this recom-
inant form has been broader than that induced by the smaller
D1–DBL2 fragment [52,56].
In addition to VAR2CSA, several conserved proteins expressed
y placental parasites have been identiﬁed [66–69]. These con-
erved proteins may  play an independent role in IE adhesion, or may
nteract with VAR2CSA to form conformational epitopes targeted
y naturally acquired immunity. One example is the invari-
nt protein PfCSAL that interacts with VAR2CSA (Keitany, Duffy,
t al., unpublished data). Further studies of PFI1785w, an exported
rotein exclusively expressed by placental parasites, are required
o determine whether it also has a role in inducing protective
mmunity.
The development of a placental malaria vaccine is based on
aturally occurring immunity. Based on this model, the vaccine is
redicted to induce antibodies in nulligravidae that will be boosted
y malaria exposures during subsequent pregnancies, and simi-
arly should boost functional antibodies that have been acquired
y multigravidae in endemic areas. The ﬁrst ﬁeld trials will soon
egin to assess whether individual VAR2CSA immunogens may  be
ufﬁcient for inducing functional antibodies that have been associ-
ted with protection from placental malaria, or whether additional
omponents may  be required for an effective vaccine that protects
regnant women.
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